The DEA investigates and enforces the Controlled Substances Act (21 U.S.C. §§ 801 et seq.). While the agency's public profile centers on drug trafficking enforcement, its Diversion Control Division presents distinct and often career-ending risks to healthcare providers, pharmacists, and distributors involved in the lawful prescribing and dispensing of controlled substances.
DEA's Diversion Control Division regulates the manufacture, distribution, and dispensing of lawfully produced controlled substances. Special agents, diversion investigators, pharmacologists, and program analysts are specifically tasked with targeting physicians, pharmacists, and other providers suspected of diverting controlled substances to individuals who may abuse them. The division maintains a mandate to aggressively pursue healthcare providers suspected of illegally prescribing and dispensing controlled-substance medications.
Diversion investigations target: falsifying patient records for the purpose of supplying unnecessary medications; falsifying prescriptions; prescribing controlled substances without a legitimate medical purpose or outside the usual course of professional practice; selling prescriptions for cash; providing prescriptions for drugs that are not medically necessary; pharmacy dispensing without valid prescriptions; and distribution outside the closed system of legitimate pharmaceutical commerce.
For healthcare providers, DEA investigations primarily arise from: prescribing patterns identified through state Prescription Drug Monitoring Programs (PDMPs); tips from pharmacies flagging unusual prescribing volumes; death investigations involving prescription drugs; and coordinated enforcement actions targeting specific prescribing networks. CMS has established the Medicare Part D Overutilization Monitoring System (OMS) to monitor drug utilization—information from this database frequently drives the direction of criminal diversion investigations.
In addition to the DEA and CMS, the HHS Office of Inspector General, the Department of Justice, the FBI, and State Medicaid fraud control units conduct coordinated healthcare fraud investigations and enforcement efforts. When billing fraud investigations focus on providers' prescription practices, DEA involvement is virtually certain.
In addition to criminal prosecution under 21 U.S.C. § 841, the DEA can issue an Order to Show Cause initiating administrative proceedings to revoke or suspend your DEA Certificate of Registration. For prescribers of controlled substances, revocation of DEA registration effectively ends the ability to practice in most specialties—making DEA administrative defense as critical as criminal defense.
These administrative proceedings operate under different evidentiary standards and procedural rules than criminal prosecutions. The burden of proof is lower. The rules of evidence are relaxed. And surrendering registration—which may seem like an easy exit from administrative proceedings—can create devastating collateral consequences including adverse inference in parallel criminal matters.
DEA investigations require simultaneous defense of both criminal and administrative proceedings. Statements made in one forum can be used in the other. Surrendering registration to resolve administrative matters can be characterized as consciousness of guilt in criminal proceedings. Every decision must account for both tracks.
Early legal intervention can significantly impact the outcome of a federal investigation or prosecution.
Mansoor Broachwala, Esq. — Licensed in Illinois since 2017
ATTORNEY ADVERTISING. This website is for informational purposes only. Visiting this website does not create an attorney-client relationship. Do not submit confidential information until an engagement agreement has been executed. Past results do not guarantee future outcomes.